Literature DB >> 18207030

Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck.

Allen M Chen1, Megan E Daly, Ivan El-Sayed, Joaquin Garcia, Nancy Y Lee, M Kara Bucci, Michael J Kaplan.   

Abstract

PURPOSE: To report the clinical outcome of patients treated with combined-modality approaches for sinonasal undifferentiated carcinoma (SNUC) of the head and neck. METHODS AND MATERIALS: The records of 21 patients with SNUC treated with curative intent at the University of California, San Francisco between 1990 and 2004 were analyzed. Patient age ranged from 33 to 71 years (median, 47 years). Primary tumor sites included the nasal cavity (11 patients), maxillary sinus (5 patients), and ethmoid sinus (5 patients). All patients had T3 (4 patients) or T4 (17 patients) tumors. Local-regional treatment included surgery followed by postoperative radiotherapy (PORT) with or without adjuvant chemotherapy for 17 patients; neoadjuvant chemoradiotherapy followed by surgery for 2 patients; and definitive chemoradiotherapy for 2 patients. Median follow-up among surviving patients was 58 months (range, 12-70 months).
RESULTS: The 2- and 5-year estimates of local control were 60% and 56%, respectively. There was no difference in local control according to initial treatment approach, but among the 19 patients who underwent surgery the 5-year local control rate was 74% for those with gross tumor resection, compared with 24% for those with subtotal tumor resection (p = 0.001). The 5-year rates of overall and distant metastasis-free survival were 43% and 64%, respectively. Late complications included cataracts (2 patients), lacrimal stenosis (1 patient), and sino-cutaneous fistula (1 patient).
CONCLUSION: The suboptimal outcomes suggest a need for more effective therapies. Gross total resection should be the goal of all treatments whenever possible.

Entities:  

Mesh:

Year:  2008        PMID: 18207030     DOI: 10.1016/j.ijrobp.2007.06.057

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States.

Authors:  Kyle J Chambers; Ashton E Lehmann; Aaron Remenschneider; Matthew Dedmon; Josh Meier; Stacey T Gray; Derrick T Lin
Journal:  J Neurol Surg B Skull Base       Date:  2014-09-29

2.  Craniofacial Resection for Sinonasal Malignant Tumors: Statistical Analysis of Surgical Outcome over 17 Years at a Single Institution.

Authors:  Seiichiro Mine; Naokatsu Saeki; Kentaro Horiguchi; Toyoyuki Hanazawa; Yoshitaka Okamoto
Journal:  Skull Base       Date:  2011-07

3.  Sinonasal Undifferentiated Carcinoma: A 15-Year Single Institution Experience.

Authors:  Alan D Workman; Robert M Brody; Edward C Kuan; Esther Baranov; Steven G Brooks; Michelle Alonso-Basanta; Jason G Newman; Christopher H Rassekh; Ara A Chalian; Alexander G Chiu; Gregory S Weinstein; Michael D Feldman; Nithin D Adappa; Bert W O'Malley; James N Palmer
Journal:  J Neurol Surg B Skull Base       Date:  2018-08-16

Review 4.  Management of olfactory neuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma involving the skullbase.

Authors:  Gautam U Mehta; Shaan M Raza; Shirley Y Su; Ehab Y Hanna; Franco DeMonte
Journal:  J Neurooncol       Date:  2020-05-18       Impact factor: 4.130

5.  Survival in unresectable sinonasal undifferentiated carcinoma treated with concurrent intra-arterial cisplatin and radiation.

Authors:  Sonal S Noticewala; Loren K Mell; Scott E Olson; William Read
Journal:  World J Clin Cases       Date:  2015-02-16       Impact factor: 1.337

6.  Sinonasal Carcinomas with Neuroendocrine Features: Histopathological Differentiation and Treatment Outcomes.

Authors:  Liuba Soldatova; Raewyn G Campbell; Ricardo L Carrau; Daniel M Prevedello; Paul Wakely; Bradley A Otto; Leo F Ditzel Filho
Journal:  J Neurol Surg B Skull Base       Date:  2016-04-26

7.  A comprehensive comparative analysis of treatment modalities for sinonasal malignancies.

Authors:  Tyler P Robin; Bernard L Jones; Oren M Gordon; Andy Phan; Diana Abbott; Jessica D McDermott; Julie A Goddard; David Raben; Ryan M Lanning; Sana D Karam
Journal:  Cancer       Date:  2017-04-03       Impact factor: 6.860

8.  Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma.

Authors:  Moran Amit; Ahmed S Abdelmeguid; Teemaranawich Watcherporn; Hideaki Takahashi; Samantha Tam; Diana Bell; Renata Ferrarotto; Bonnie Glisson; Michael E Kupferman; Dianna B Roberts; Shirley Y Su; Shaan M Raza; Franco DeMonte; Ehab Y Hanna
Journal:  J Clin Oncol       Date:  2019-01-07       Impact factor: 44.544

9.  Sinonasal undifferentiated carcinoma: a 13-year experience at a single institution.

Authors:  Erin M Lin; Anthony Sparano; Aaron Spalding; Avraham Eisbruch; Francis P Worden; Jason Heth; Stephen E Sullivan; B Gregory Thompson; Lawrence J Marentette
Journal:  Skull Base       Date:  2010-03

10.  Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.

Authors:  Nicole G Chau; Shelley Hurwitz; Chelsey M Mitchell; Alexandra Aserlind; Noam Grunfeld; Leah Kaplan; Peter Hsi; Daniel E Bauer; Christopher S Lathan; Carlos Rodriguez-Galindo; Roy B Tishler; Robert I Haddad; Stephen E Sallan; James E Bradner; Christopher A French
Journal:  Cancer       Date:  2016-08-10       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.